scholarly article | Q13442814 |
P356 | DOI | 10.1038/S41375-020-0727-Y |
P698 | PubMed publication ID | 32042081 |
P50 | author | Jasmin Bahlo | Q108428543 |
Ursula Vehling-Kaiser | Q47158556 | ||
Barbara Eichhorst | Q47158788 | ||
Stephan Stilgenbauer | Q47158807 | ||
P2093 | author name string | Michael Hallek | |
Andreas Bühler | |||
Dirk Winkler | |||
Georg Hopfinger | |||
Hartmut Döhner | |||
Raymonde Busch | |||
Ulrich Jäger | |||
Lothar Müller | |||
Harald Fuss | |||
Michael Starck | |||
Martin Bentz | |||
Carmen D Herling | |||
Kirsten Fischer | |||
Frank Hartmann | |||
Bertold Emmerich | |||
Werner Freier | |||
Wolfgang Abenhardt | |||
Georg Jacobs | |||
Sandra Robrecht | |||
Clemens Wendtner | |||
Hans Jürgen Hurtz | |||
Ilona Blau | |||
Manuela A Hoechstetter | |||
Maria Goebeler | |||
Michael J Eckart | |||
P2860 | cites work | Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia | Q47812640 |
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. | Q55036524 | ||
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study | Q60596975 | ||
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact | Q64091853 | ||
Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance | Q70026398 | ||
Defining the prognosis of early stage chronic lymphocytic leukaemia patients | Q82972787 | ||
The CLL-IPI applied in a population-based cohort | Q88291952 | ||
Growth dynamics in naturally progressing chronic lymphocytic leukaemia | Q92382869 | ||
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients | Q93055959 | ||
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up | Q27851444 | ||
Recurrent mutations refine prognosis in chronic lymphocytic leukemia. | Q27853022 | ||
Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 | ||
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data | Q31096565 | ||
Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia | Q33455289 | ||
The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience | Q33707448 | ||
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia | Q33852805 | ||
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis | Q34282319 | ||
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma | Q34403901 | ||
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia | Q34418874 | ||
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia | Q36843749 | ||
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment | Q36961269 | ||
Validation of a new prognostic index for patients with chronic lymphocytic leukemia | Q37068125 | ||
Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? | Q38680890 | ||
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group | Q40084503 | ||
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. | Q40365566 | ||
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. | Q42336286 | ||
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. | Q42711562 | ||
Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters | Q42925708 | ||
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia | Q44078664 | ||
Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. | Q44279397 | ||
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia | Q44904842 | ||
P433 | issue | 4 | |
P921 | main subject | multicenter clinical trial | Q6934595 |
P304 | page(s) | 1038-1051 | |
P577 | publication date | 2020-02-10 | |
P1433 | published in | Leukemia | Q6534498 |
P1476 | title | Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group | |
P478 | volume | 34 |
Q94562886 | Chronic lymphocytic leukemia in 2020: a surfeit of riches? |
Q99557890 | Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia |
Q101051264 | Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients |
Search more.